Literature DB >> 3562481

Chronic haloperidol effects on oral movements and radial-arm maze performance in rats.

E D Levin, D M Galen, G D Ellison.   

Abstract

Rats were examined for the development of adverse motor and cognitive effects during and after 24 weeks of chronic haloperidol (HAL) administration using an 8-arm maze and a computerized apparatus for measuring spontaneous oral movements. In the maze, HAL caused a significant decline in choice accuracy only during the first week of administration, whereas it caused a significant decline in locomotor speed throughout drug administration. There were no effects of HAL on maze behavior after withdrawal. Haloperidol reduced the number of mouth movements during drug administration, but after withdrawal there was a significant increase. This replicated a previous finding from our lab. The oral movements which did occur in the HAL-treated rats were slower than normal. The timing of the HAL-induced cognitive dysfunction was similar to the Parkinson-like disorder shown by patients given chronic neuroleptics, whereas the timing of the increase in oral movements after the withdrawal of HAL was more related to the appearance of tardive dyskinesia. There was evidence in both tests of a persisting sedation during chronic neuroleptic administration.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3562481     DOI: 10.1016/0091-3057(87)90523-5

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  11 in total

1.  Radial-arm maze performance in rats is impaired by a combination of nicotinic-cholinergic and D2 dopaminergic antagonist drugs.

Authors:  S R McGurk; E D Levin; L L Butcher
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 2.  Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia.

Authors:  J L Waddington
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

3.  Negative effects of chronic oral chlorpromazine and olanzapine treatment on the performance of tasks designed to assess spatial learning and working memory in rats.

Authors:  A V Terry; S E Warner; L Vandenhuerk; A Pillai; S P Mahadik; G Zhang; M G Bartlett
Journal:  Neuroscience       Date:  2008-08-27       Impact factor: 3.590

4.  Chronic neuroleptic effects on spatial reversal learning in monkeys.

Authors:  E D Levin; L M Gunne
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  Rats administered chronic neuroleptics develop oral movements which are similar in form to those in humans with tardive dyskinesia.

Authors:  G Ellison; R E See
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  Intermittent and continuous haloperidol regimens produce different types of oral dyskinesias in rats.

Authors:  R E See; G Ellison
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 7.  Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.

Authors:  Edward D Levin; Amir H Rezvani
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

8.  Effect of chronic trifluoperazine administration and subsequent withdrawal on the production and persistence of perioral behaviours in two rat strains.

Authors:  P Collins; C L Broekkamp; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

9.  Tremorous mouth movements in rats administered chronic neuroleptics.

Authors:  G Ellison; R See; E Levin; J Kinney
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

10.  Protracted effects of chronic oral haloperidol and risperidone on nerve growth factor, cholinergic neurons, and spatial reference learning in rats.

Authors:  A V Terry; D A Gearhart; S Warner; E J Hohnadel; M-L Middlemore; G Zhang; M G Bartlett; S P Mahadik
Journal:  Neuroscience       Date:  2007-09-14       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.